Shake-up at Prime claims CEO Gottesdiener, 25% of staff

Amid several changes at Prime Medicine Inc. (NASDAQ:PRME), CEO Keith Gottesdiener is stepping down and leaving the biotech’s board. CFO Allen Reine will assume the CEO role and join the board, while Jeff Marrazzo will become chairman.

Prime is also laying off 25% of its staff and seeking a partner for PM359, its genetic therapy for chronic granulomatous disease. Although the company believes new data from a Phase I/II study of the treatment represent proof of concept for its platform, the company will instead prioritize therapies for Wilson disease and AAT deficiency...